Prelude Capital Management’s Exact Sciences EXAS Stock Holding History

Prelude Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-800	Closed	-$16K	–	1969
2014 Q3	$16K	Buy	+800	New	+$14.7K	﹤0.01%	1754
2014 Q2	–	Sell	-1,000	Closed	-$14K	–	1985
2014 Q1	$14K	Buy	+1,000	New	+$13.5K	﹤0.01%	1734
2013 Q4	–	Sell	-5,000	Closed	-$59K	–	1701
2013 Q3	$59K	Sell	5,000 -2,000	-29%	-$25.7K	0.01%	907
2013 Q2	$97K	Buy	+7,000	New	+$76K	0.02%	658

Other funds holding EXAS

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PRS

Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Prelude Capital Management's EXAS Position: Q1 2026 in Review

Prelude Capital Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 131,830 shares — an estimated $13.4M sold.

Prelude Capital Management first reported a position in EXAS in Q2 2014 and held it in 15 quarters. The position peaked at $13.4M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

Prelude Capital Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 131,830 Exact Sciences shares in Q1 2026, an estimated $13.4M.
Prelude Capital Management first reported a position in Exact Sciences in Q2 2014 and held it in 15 quarters.
Prelude Capital Management's Exact Sciences position peaked at $13.4M in Q4 2025.
7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.